Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review

Date: March 16, 2016
Pages: 89
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ED84A4E2CF3EN
Leaflet:

Download PDF Leaflet

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review
Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Eli Lilly and Company (Lilly) is a global healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines in the fields of cardiovascular, diabetes, cancer, neuroscience, critical care, men's health and musculoskeletal. It also provides pet medicine, food-safety products and services to the food animal industry and companion animal health products. Lilly is also has mid-to-late stage pipeline portfolio representing a variety of therapeutic areas including diabetes, cancer, neuroscience and autoimmunity. The company distributes human pharmaceutical and animal health products primarily through independent wholesale distributors.

Eli Lilly and Company Key Recent Developments

Feb 24,2016 Indiana Biosciences Research Institute Announces $100 Million in Grants Supporting Scientific Innovation to Address Metabolic Disease and Poor Nutrition
Feb 23,2016 Major pharma companies sign up to groundbreaking Parkinson’s consortium
Feb 11,2016 Lilly Diabetes Helps Inspiring Students With Type 1 Diabetes Attend College Through Scholarship Donation
Jan 28,2016 Lilly Reports Fourth-Quarter And Full-Year 2015 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Eli Lilly and Company - Key Facts
Eli Lilly and Company - Key Employees
Eli Lilly and Company - Key Employee Biographies
Eli Lilly and Company - Major Products and Services
Eli Lilly and Company - Pharmaceutical Pipeline Products Data
Eli Lilly and Company, Pipeline Products by Therapy Area
Eli Lilly and Company, Pipeline Products by Development Phase
Eli Lilly and Company - History
Eli Lilly and Company - Company Statement
Eli Lilly and Company - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Eli Lilly and Company - Key Manufacturing Facilities
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Eli Lilly and Company - Business Description
Business Description - Animal Health Products
Animal Health Products - Overview
Animal Health Products - Financials
Business Description - Human Pharmaceutical Products
Human Pharmaceutical Products - Overview
Human Pharmaceutical Products - Financials
Eli Lilly and Company - Corporate Strategy
Eli Lilly and Company - SWOT Analysis
SWOT Analysis - Overview
Eli Lilly and Company - Strengths
Strength - Emphasis on Research
Strength - Established Presence: Endocrinology Product Market
Strength - Lilly Oncology
Eli Lilly and Company - Weaknesses
Weakness - Insufficient Efficacy
Weakness - Product Defects
Eli Lilly and Company - Opportunities
Opportunity - Strategic Collaborations
Opportunity - Product Pipeline
Opportunity - Strategic Acquisitions
Eli Lilly and Company - Threats
Threat - Influx of Generics
Threat - Product Litigations
Threat - Competitive Pressures
Eli Lilly and Company - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eli Lilly and Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eli Lilly and Company, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Eli Lilly and Company, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 24, 2016: Indiana Biosciences Research Institute Announces $100 Million in Grants Supporting Scientific Innovation to Address Metabolic Disease and Poor Nutrition
Feb 23, 2016: Major pharma companies sign up to groundbreaking Parkinson’s consortium
Feb 11, 2016: Lilly Diabetes Helps Inspiring Students With Type 1 Diabetes Attend College Through Scholarship Donation
Jan 28, 2016: Lilly Reports Fourth-Quarter And Full-Year 2015 Results
Jan 19, 2016: Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration
Jan 05, 2016: Lilly Announces 2016 Financial Guidance, Updates 2015 Expectations
Dec 15, 2015: Juan R. Luciano elected to Lilly board of directors
Nov 02, 2015: Eli Lilly and Company Announces Expansion of Indianapolis R&D Headquarters
Oct 30, 2015: Feds Investigate Lilly Over Drug Pricing Policies
Oct 22, 2015: Lilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Eli Lilly and Company, Key Facts
Eli Lilly and Company, Key Employees
Eli Lilly and Company, Key Employee Biographies
Eli Lilly and Company, Major Products and Services
Eli Lilly and Company, Number of Pipeline Products by Therapy Area
Eli Lilly and Company, Number of Pipeline Products by Development Stage
Eli Lilly and Company, Pipeline Products By Therapy Area and Development Phase
Eli Lilly and Company, History
Eli Lilly and Company, Subsidiaries
Eli Lilly and Company, Key Manufacturing Facilities
Eli Lilly and Company, Joint Venture
Eli Lilly and Company, Key Competitors
Eli Lilly and Company, Ratios based on current share price
Eli Lilly and Company, Annual Ratios
Eli Lilly and Company, Interim Ratios
Eli Lilly and Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eli Lilly and Company, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Eli Lilly and Company, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Eli Lilly and Company, Pipeline Products by Therapy Area
Eli Lilly and Company, Pipeline Products by Development Phase
Eli Lilly and Company, Performance Chart (2011 - 2015)
Eli Lilly and Company, Ratio Charts
Eli Lilly and Company, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eli Lilly and Company, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: